NCT02135042

Individualized Treatment in Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA

RecruitingPHASE2, PHASE3INTERVENTIONAL

Trial Details

Start: 2014-07-01Est. Completion: 2026-12-01

Enrollment target: 924 participants

Locations

University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
The Kirklin Clinic at Acton Road, Birmingham, Alabama, United States
Banner University Medical Center - Tucson, Tucson, Arizona, United States
Sutter Cancer Centers Radiation Oncology Services-Auburn, Auburn, California, United States
Alta Bates Summit Medical Center-Herrick Campus, Berkeley, California, United States
Mills-Peninsula Medical Center, Burlingame, California, United States
Sutter Cancer Centers Radiation Oncology Services-Cameron Park, Cameron Park, California, United States
City of Hope Comprehensive Cancer Center, Duarte, California, United States
Kaiser Permanente Dublin, Dublin, California, United States
Fresno Cancer Center, Fresno, California, United States
UC San Diego Moores Cancer Center, La Jolla, California, United States
Memorial Medical Center, Modesto, California, United States
Kaiser Permanente Oakland-Broadway, Oakland, California, United States
UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California, United States

B Acute Lymphoblastic Leukemia

This pilot trial assesses the effect of the combination of blinatumomab with dasatinib or imatinib and standard chemothe…

Birmingham, United StatesEst. completion Dec 1, 2030

B Acute Lymphoblastic Leukemia, Philadelphia Chromosome NegativeRecurrent B Acute Lymphoblastic LeukemiaRefractory B Acute Lymphoblastic Leukemia

This phase II trial studies how well inotuzumab ozogamicin and blinatumomab with or without ponatinib work in treating p…

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.